Small Intestinal Bacterial Overgrowth Treatment Market By Therapy Type (Antibiotic Therapy [Rifaximin, Neomycin, Metronidazole, Other Antibiotics], Dietary Interventions [Low-FODMAP Diet, Low-Fermentation Diet, Elemental Diet], Prokinetics & Adjunctive Therapies, Herbal & Natural Antimicrobials [Berberine, Oregano-Derived Formulations, Neem, Allicin-Based Products]); By Indication/Underlying Condition (IBS-Associated SIBO, Motility Disorder-Associated SIBO, Anatomical & Structural Alteration-Associated SIBO, Medication-Induced SIBO, Other Comorbid Disease-Associated SIBO [Celiac Disease, Liver Disease, Inflammatory Bowel Disease]); By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Are Rifaximin Therapy and Recurrence Management Shaping the Small Intestinal Bacterial Overgrowth Treatment Market?

The Global Small Intestinal Bacterial Overgrowth Treatment Market was valued at USD 548 million in 2025 and is projected to reach USD 835 million by 2032, expanding at a CAGR of 6.2% during 2026–2032.

 

Small intestinal bacterial overgrowth, or SIBO, occurs when excessive bacteria accumulate in the small intestine and cause symptoms such as bloating, abdominal discomfort, diarrhea, constipation, and poor nutrient absorption. Treatment is centered mainly on targeted oral antibiotics, dietary management, and correction of underlying problems such as impaired intestinal motility.

 

Rifaximin is widely used as a first-line therapy, particularly for hydrogen-dominant SIBO, and treatment commonly lasts around 7–14 days. Clinical studies report bacterial eradication or normalization rates of roughly 63%–80% with rifaximin. Methane-associated intestinal overgrowth is often treated with a combination of rifaximin and neomycin, while metronidazole and other antibiotics may be used as alternatives in selected patients.

 

The addressable patient pool is significant because SIBO is frequently associated with other gastrointestinal disorders. Estimates suggest that approximately 6%–15% of otherwise healthy adults may have SIBO, while prevalence has been reported at around 30%–80% among patients with irritable bowel syndrome and approximately 31% among patients with inflammatory bowel disease.

 

North America, particularly the United States, remains commercially important due to established gastroenterology care, wider access to breath testing, and frequent use of rifaximin-based therapy. Salix Pharmaceuticals, a Bausch Health company, is a major participant through XIFAXAN. Market expansion is supported by improving diagnosis, the large gastrointestinal patient pool, and frequent recurrence that can lead to repeat testing and additional treatment courses.

 

Which SIBO Treatment Segments Are Leading the Market and Which Are Growing Fastest?

By Therapy Type: Antibiotics Lead as Herbal Alternatives Gain Ground

Leading Subsegment – Antibiotic Therapy

Antibiotic therapy represents the largest treatment category in the Small Intestinal Bacterial Overgrowth Treatment Market, accounting for approximately 56% share and USD 306.9 million in 2025, with the segment expected to reach nearly USD 455.4 million by 2032 at a CAGR of 5.8% during 2026–2032. Antibiotics remain the primary medical approach for reducing excessive bacterial populations in the small intestine, relieving bloating, abdominal discomfort, diarrhea, and related gastrointestinal symptoms while helping normalize abnormal breath-test findings among diagnosed SIBO patients.

Fastest-Growing Subsegment – Herbal and Natural Antimicrobials

Herbal and natural antimicrobial therapies account for approximately 12% of the Small Intestinal Bacterial Overgrowth Treatment Market, valued at USD 65.8 million in 2025, and are projected to record the fastest therapy CAGR of 8.1% through 2032, reaching nearly USD 113.5 million. Herbal antimicrobial regimens are increasingly used as alternative or add-on treatments for SIBO, with clinical studies reporting outcomes comparable to rifaximin in selected patients, supporting wider consideration of non-antibiotic treatment approaches for bacterial overgrowth management.

 

By Indication / Underlying Condition: IBS Leads as Motility Disorders Drive Repeat Care

Leading Subsegment – IBS-Associated SIBO

IBS-associated SIBO leads the indication category with approximately 43% share, representing USD 235.6 million in 2025 and projected to reach USD 361.3 million by 2032 at a 6.3% CAGR. A large proportion of IBS patients with bacterial overgrowth require targeted treatment using antibiotics, dietary management, probiotics, and recurrence-control approaches. Identifying SIBO as an underlying contributor to bloating, abdominal pain, diarrhea, and altered bowel habits expands treatment opportunities beyond conventional IBS symptom management, supporting continued use of SIBO-focused therapies.

Fastest-Growing Subsegment – Motility Disorder-Associated SIBO

Motility disorder-associated SIBO accounted for approximately 24% of the Small Intestinal Bacterial Overgrowth Treatment Market, representing about USD 131.5 million in 2025, and is projected to post the fastest indication CAGR of 7.2% through 2032. Impaired intestinal motility prevents normal gut clearing, allowing bacteria to repeatedly accumulate in the small intestine. Frequent recurrence creates a need for antibiotics combined with prokinetic medications, supporting longer treatment periods, repeat prescriptions, and ongoing clinical management for patients with underlying motility disorders.

 

By Distribution Channel: Retail Pharmacies Lead as Digital Access Expands

Leading Subsegment – Retail Pharmacies

Retail pharmacies account for the largest distribution share in the Small Intestinal Bacterial Overgrowth Treatment Market, representing approximately 46% and USD 252.1 million in 2025. The segment is projected to expand at a 5.8% CAGR to USD 374.1 million by 2032. Retail pharmacies play a central role in dispensing SIBO therapies, including rifaximin and other prescribed antibiotics, while providing medication guidance for patients completing multi-week treatment courses and managing recurrent SIBO episodes requiring repeat prescriptions or supportive therapies.

Fastest-Growing Subsegment – Online Pharmacies

Online pharmacies account for approximately 20% of the Small Intestinal Bacterial Overgrowth Treatment Market, representing USD 109.6 million in 2025, and are projected to record the fastest distribution-channel CAGR of 9.1% during 2026–2032. The channel provides convenient access to prescription therapies used in SIBO management, including specialized non-absorbable antibiotics such as rifaximin. Home delivery, digital prescription processing, easier refill access, and potential cost savings make online pharmacies increasingly relevant for patients requiring repeated or extended treatment courses.

 

By Geography: North America Leads as Asia-Pacific Treatment Adoption Accelerates

Leading Subsegment – North America

North America leads the Small Intestinal Bacterial Overgrowth Treatment Market, accounting for approximately 39% of the global market and USD 213.7 million in 2025. Treatment across the region primarily involves targeted antibiotics, dietary management, and therapies addressing underlying motility or gastrointestinal disorders, supported by rising clinical recognition of SIBO and recurrent cases requiring continued care. The regional market is projected to expand at a 5.9% CAGR, reaching approximately USD 319.2 million by 2032.

Fastest-Growing Subsegment – Asia-Pacific

Asia-Pacific accounts for approximately 24% of the Small Intestinal Bacterial Overgrowth Treatment Market, valued at USD 131.5 million in 2025, and is projected to record the fastest regional CAGR of 7.8% during 2026–2032, reaching nearly USD 222.5 million by 2032. Treatment adoption is supported by regional clinical guidance, including consensus recommendations from the Indian Neurogastroenterology and Motility Association (INMA), which help physicians improve SIBO diagnosis and establish more consistent approaches to antibiotic therapy, recurrence management, and underlying motility-related conditions.

 

Which Companies Are Leading the Small Intestinal Bacterial Overgrowth Treatment Market?

Bausch Health / Salix Pharmaceuticals – Leading Through Rifaximin-Based Gastrointestinal Therapy

Bausch Health, through Salix Pharmaceuticals, is one of the most commercially relevant companies in the SIBO treatment landscape because of XIFAXAN (rifaximin), a gut-directed antibiotic extensively used in gastroenterology. Rifaximin has very low systemic absorption and acts primarily within the gastrointestinal tract, making it particularly relevant for reducing abnormal intestinal bacterial loads. Although SIBO is not currently an FDA-approved indication for XIFAXAN in the United States, rifaximin is widely studied and clinically used off-label for SIBO. A systematic review of 32 studies involving 1,331 SIBO patients reported an overall bacterial-eradication rate of 70.8% with rifaximin, while 67.7% of patients with successful eradication experienced symptom improvement or resolution.

The commercial strength of this therapy is reflected in Bausch Health's gastrointestinal business. The company's Salix segment generated USD 2.58 billion in revenue during 2025, up 11% from USD 2.33 billion in 2024. XIFAXAN represented approximately 85% of Salix segment revenue, making it by far the segment's largest product franchise. In the fourth quarter of 2025 alone, XIFAXAN generated USD 607 million, an increase of 10% year over year. These figures include all approved XIFAXAN indications rather than SIBO alone, but they demonstrate the scale of the rifaximin treatment platform relevant to SIBO management.

Alfasigma – Originator of Rifaximin and a Major Gastrointestinal Drug Specialist

Alfasigma is another major company relevant to SIBO treatment because it originally developed rifaximin, the molecule that has become one of the most extensively investigated antibiotics for bacterial overgrowth in the small intestine. The company developed rifaximin in its Italian laboratories in 1980, specifically targeting local antibacterial activity in the gastrointestinal tract with minimal systemic absorption. It later commercialized the drug under brands including Normix, while rifaximin subsequently became available internationally through licensing and commercial partnerships.

Gastroenterology remains one of Alfasigma's core therapeutic areas, with rifaximin-α forming an important part of its portfolio. Alfasigma reports that its products are now available across more than 100 countries, supported by 27 international offices, while the company generated approximately EUR 1.8 billion in total turnover in 2025. Its rifaximin franchise also has meaningful commercial scale: Alfasigma reported that Normix generated almost EUR 60 million in turnover in Italy in 2023, while Normix and Enterolactis together exceeded EUR 117 million.

Other Relevant Companies and Their Role in SIBO Treatment:

• Sun Pharmaceutical Industries: Markets RIFAGUT and RIFLECT rifaximin tablets in 200 mg, 400 mg and 550 mg strengths in India, extending access to rifaximin-based gastrointestinal antimicrobial therapy.

• Lupin Limited: Participates in the rifaximin ecosystem through gastrointestinal formulations and its ZAXINE 550 mg licensing and distribution relationship with Salix in Canada, supported by its specialty gastroenterology commercial infrastructure.

• Cipla: Has developed and commercialized rifaximin-based gastrointestinal products such as Rixmin and has previously contributed rifaximin-complex intellectual property through licensing arrangements, giving it a role in expanding alternative rifaximin formulations.

 

Analyst Commentary: How Will Recurrence Control Shape the Next Phase of SIBO Treatment?

The Small Intestinal Bacterial Overgrowth Treatment Market is gradually shifting from short-term bacterial eradication toward treatment strategies that address recurrence, intestinal motility, and underlying gastrointestinal conditions. The strongest growth opportunities are developing around gut-targeted antibiotics such as rifaximin, combination therapy for methane-associated overgrowth, prokinetic treatment for recurrent SIBO, and more structured dietary and microbiome-focused management. Increasing recognition of SIBO among patients with IBS, gastroparesis, chronic constipation, and other motility disorders is also expanding the diagnosed treatment population.

 

Small Intestinal Bacterial Overgrowth Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 548 Million
Revenue Forecast in 2032	USD 835 Million
Overall Growth Rate	CAGR of 6.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Therapy Type, By Indication / Underlying Condition, By Distribution Channel, By Geography
By Therapy Type	Antibiotic Therapy, Dietary Interventions, Prokinetics and Adjunctive Therapies, Herbal and Natural Antimicrobials
By Indication / Underlying Condition	IBS-Associated SIBO, Motility Disorder-Associated SIBO, Anatomical and Structural Alteration-Associated SIBO, Medication-Induced SIBO, Other Comorbid Disease-Associated SIBO
By Distribution Channel	Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing recognition and diagnosis of SIBO, large gastrointestinal patient population, widespread use of rifaximin-based therapy, high prevalence among IBS and motility-disorder patients, recurring disease requiring repeat treatment, growing use of combination therapy for methane-associated overgrowth, expanding prokinetic treatment, dietary management, and increasing access to online pharmacy channels
Customization Option	Available upon request